Check out our most popular compounded medications! Get Started
Bayview Pharmacy's Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray is a liquid formulation delivered in a spray form for nasal administration. It is a prescription medication used for the treatment of conditions such as migraine, cluster headache, Meniere's disease, tension-type headache, and post-traumatic headache.
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray is a specialized prescription medication specifically designed to alleviate the symptoms of migraine headaches. It functions by constricting the blood vessels in the brain, thereby reducing the pain associated with migraines. This unique formulation is delivered in a liquid spray form, designed for direct administration into the nasal cavity. This method of delivery allows for targeted local or systemic effects, providing rapid relief from migraine symptoms.
It is generally well-tolerated by most patients, with minimal side effects. However, some patients may experience common side effects such as nausea, dizziness, and drowsiness. It is important for patients to be aware that this medication may interact with other medications. Therefore, it is recommended to consult with a healthcare professional or pharmacist before starting any new medications while using this nasal spray.
We proudly offer Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray as a reliable solution for managing migraine headaches. If you have any questions or concerns about this formulation or any other medications, please do not hesitate to contact us. Our team is always ready to assist you in finding the best treatment options for your specific needs.
Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray is a liquid formulation specifically designed for administration into the nasal cavity. It is indicated for the acute treatment of migraine with or without aura in adults. However, it is not suitable for treating cluster headaches. This medication should not be used in patients with ischemic heart disease, peripheral vascular disease, or uncontrolled hypertension. It is also contraindicated in patients with a history of stroke, transient ischemic attack, or hemiplegic or basilar migraine.
Patients should be advised to avoid activities requiring mental alertness until they understand how this medication affects them. It is also important to avoid alcohol and other medications that may interact with Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray. These include, but are not limited to, ergot-containing medications, triptans, serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and certain antibiotics.
Patients should inform their healthcare provider if they are taking any of these medications. They should also inform their healthcare provider if they are pregnant, planning to become pregnant, or breastfeeding. The effects of Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray on an unborn baby or its passage into breast milk are currently unknown.
If you have any questions about Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray or its interactions, please do not hesitate to reach out for further information.
Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray is a specialized medication formulated to alleviate the symptoms of migraine headaches. It functions by constricting the blood vessels in the brain, thereby reducing inflammation and mitigating pain. Additionally, it aids in decreasing nausea and hypersensitivity to light and sound, common symptoms associated with migraines.
This medication is delivered in a liquid formulation via a nasal spray, designed specifically for administration into the nasal cavity. This method of delivery not only ensures targeted local or systemic effects but also offers the convenience of use and rapid relief from symptoms.
To administer the nasal spray, the patient should first clear their nasal passage by blowing their nose. Following this, the head should be tilted back slightly. The nozzle of the spray is then inserted into one nostril, and the pump is pressed to release the medication. The patient should inhale deeply to ensure the medication is properly absorbed. This process is then repeated in the other nostril. It is important to note that the patient should not exceed two sprays in each nostril per day.
While Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray is generally well-tolerated, some patients may experience side effects such as nausea, dizziness, or drowsiness. In the event of experiencing any of these side effects, patients are advised to promptly contact their healthcare provider.
If you have any queries or require further information about the usage of Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray, please do not hesitate to reach out to us. We are here to assist you in managing your health effectively.
Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray is a liquid formulation that is administered via the nasal cavity. This method of delivery allows for targeted local or systemic effects through the nostrils. This medication is primarily used to treat migraines, but it is also used off-label for other headache disorders such as chronic daily headache, hemicrania continua, and new daily persistent headache. Additionally, it can be used to alleviate symptoms such as vertigo, nausea, and vomiting that are often associated with migraines.
It is important to note that Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray is not recommended for use in children under 12 years of age. Furthermore, it is not advised for use in pregnant women due to potential harm to the fetus. Patients should be aware that this medication may affect their alertness and should therefore avoid activities such as driving or operating machinery until they understand how this medication affects them. It is also recommended that patients avoid alcohol while taking this medication.
If you have any questions or concerns about the use of Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray, please do not hesitate to reach out to us at Bayview Pharmacy. We are here to assist you with any queries you may have regarding this medication.
Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray is a liquid formulation delivered in a spray form, specifically designed for administration into the nasal cavity. It provides targeted local or systemic effects through the nostrils.
This nasal spray works by constricting blood vessels in the brain, which helps to alleviate the pain associated with migraines. The medication is absorbed through the nasal lining and enters the bloodstream, providing relief from symptoms.
You should use this nasal spray as directed by your healthcare provider. Typically, it is administered into the nostrils. Always follow the instructions provided with the medication.
Some potential side effects include nasal discomfort, dizziness, weakness, high blood pressure, and nausea. If you experience any severe or persistent side effects, you should contact your healthcare provider immediately.
You should discuss this with your healthcare provider. This medication may have potential risks during pregnancy or while breastfeeding.
It's important to discuss all medications you are currently taking with your healthcare provider before starting Dihydroergotamine Mesylate 2.5 mg/ml Nasal Spray. Some medications may interact with this nasal spray, altering its effectiveness or causing adverse effects.
If you miss a dose, take it as soon as you remember. If it is close to the time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take two doses at the same time or extra doses.
Store this medication at room temperature, away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.
If you suspect an overdose, contact a poison control center or emergency room immediately. Symptoms of overdose may include severe dizziness, fast or slow heartbeat, or fainting.
While this medication is not typically associated with dependency, it's important to use it as directed by your healthcare provider. Overuse can lead to medication overuse headache, which is a condition where headaches become worse instead of better.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Inhale intranasally
